{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-26-000059","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2026-05-12T20:01:42+00:00","discovered_at":"2026-05-12T20:03:00.467377+00:00","generated_at":"2026-05-12T21:37:52.806449+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead","bullets":["Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.","No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.","Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.","Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.","TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-26-000059","json":"https://secwatch.observer/filing/0001108205-26-000059.json","markdown":"https://secwatch.observer/filing/0001108205-26-000059.md","text":"https://secwatch.observer/filing/0001108205-26-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/0001108205-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/cris-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:37:52.806449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dd45582bb6e759587ddbc8764137da3deb6db14","claim":"CURIS INC reported for the quarter ended March 31, 2026 results: net income net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis, EPS $1.25 per share on both a basic and diluted basis.","evidence_excerpt":"On May 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/0001108205-26-000059-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis"},{"label":"EPS","value":"$1.25 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}